{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003621","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.441520+00:00","generated_at":"2026-06-07T00:59:44.403530+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AVITA reports preliminary FY2023 revenue $49.8M (+46% YoY), signs PermeaDerm distribution deal","bullets":["Q4 2023 commercial revenue ~$14.1M (+50% YoY); full-year 2023 commercial revenue ~$49.8M (+46% YoY).","FY2023 gross margin ~84.5%; cash, equivalents and marketable securities ~$89.1M as of Dec 31, 2023.","FY2024 revenue guidance $78.5M–$84.5M (+57%–69% YoY); Q1 2024 guidance $14.8M–$15.6M (+42%–50% YoY).","Exclusive multi-year distribution agreement with Stedical Scientific for PermeaDerm in the US; 5-yr initial term, 50% gross margin on sales.","Completed enrollment in TONE post-market vitiligo study (109 patients); 12-month follow-up with 6-month primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003621","json":"https://secwatch.observer/filing/0000950170-24-003621.json","markdown":"https://secwatch.observer/filing/0000950170-24-003621.md","text":"https://secwatch.observer/filing/0000950170-24-003621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/rcel-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:59:44.403530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"058a2059adbcf6c95ee9d683c386c2ae56134549","claim":"AVITA Medical, Inc. reported first quarter and full-year 2024 results: revenue range of $14.8 to $15.6 million and $78.5 to $84.5 million. Guidance reaffirmed.","evidence_excerpt":"committed to sustaining growth and building our business in 2024.” 2024 Financial Guidance • Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth at the lower bound of approximately 42% and upper bound of approximately 50% over the same period in the prior year • Commercial revenue for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter and full-year 2024"},{"label":"Revenue","value":"range of $14.8 to $15.6 million and $78.5 to $84.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ec590ca8dd20f8bf3849398cd7596092cec7a7f8","claim":"AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue approximately $14.1 million and approximately $49.8 million.","evidence_excerpt":"its post-market study, TONE. Preliminary Fourth Quarter and Full-Year 2023 Financial Highlights • Commercial revenue for the fourth quarter 2023 is expected to be approximately $14.1 million, an increase of approximately 50% compared to same period in 2022 • Commercial revenue for the full-year 2023 is expected to be approximately $49.8 million, an increase of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year ended December 31, 2023"},{"label":"Revenue","value":"approximately $14.1 million and approximately $49.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"dc57b686ad0b9956e5276abc1c12ccbcdd079c30","claim":"AVITA Medical, Inc. entered into Distribution Agreement with Stedical Scientific, Inc. valued at Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a (effective 2024-01-10).","evidence_excerpt":"On January 10, 2024, AVITA Medical Americas LLC (“AVITA Americas”), a wholly-owned subsidiary of AVITA Medical, Inc., (the “Company”) entered into an exclusive multi-year distribution agreement (“Agreement”) with Stedical Scientific, Inc. (“Stedical Scientific”) to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Stedical Scientific, Inc."},{"label":"Value","value":"Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a"},{"label":"Effective","value":"2024-01-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}